TLR2 and acute myeloid leukemia: These findings robustly support the notion that TLR2 pep-orid-liposome facilitates delivery of the drug specifically to tumor sites, thus minimizing off-target effects in the liver while maximizing therapeutic efficacy against AML cancer cells.